Wilson's Disease Diagnosis and Management

Clinical Presentation and Diagnosis

The American Association for the Study of Liver Diseases recommends considering Wilson's disease in any individual between ages 3 and 45 years with unexplained liver abnormalities, though cases have been diagnosed from age 5 to the eighth decade of life 1, 2
Kayser-Fleischer rings are the hallmark visual finding in Wilson's disease, appearing as golden-brownish pigment deposits in Descemet's membrane of the cornea near the limbus, and are present in 50-62% of patients with predominantly hepatic presentations at diagnosis 1, 2
Slit-lamp examination by an experienced observer is mandatory for detection of Kayser-Fleischer rings, as these rings are not always visible by direct inspection 1, 2
The diagnostic approach for Wilson's disease includes slit-lamp examination for Kayser-Fleischer rings, serum ceruloplasmin, 24-hour urinary copper excretion, hepatic copper concentration on liver biopsy, serum copper levels, and ATP7B mutation analysis when diagnosis remains uncertain after clinical and biochemical testing 1, 2, 3, 4, 5, 7

In acute liver failure presentations, specific features distinguish Wilson's disease, including Coombs-negative hemolytic anemia with intravascular hemolysis, modest aminotransferase elevations, and markedly low or normal alkaline phosphatase 3, 6, 7
Autoimmune hepatitis mimicry is common, particularly in children and young adults, and all such patients must be carefully evaluated for Wilson's disease before initiating corticosteroid therapy 3, 5, 7

The American Association for the Study of Liver Diseases recommends lifelong treatment for Wilson's disease, which must be maintained throughout pregnancy, as interruption has resulted in acute liver failure 7, 8
Treatment options include chelating agents, zinc salts, and liver transplantation for acute liver failure or decompensated cirrhosis unresponsive to medical therapy 7, 8
Presymptomatic patients identified through family screening should begin treatment immediately, with zinc preferred for children under age 3 years and either zinc or chelators effective for older individuals 7

All first-degree relatives of patients with Wilson's disease must be screened, as presymptomatic treatment prevents disease progression and improves outcomes 7
Screening should include history and physical examination, serum ceruloplasmin and copper levels, liver function tests, slit-lamp examination for Kayser-Fleischer rings, and consider ATP7B haplotype analysis or mutation testing 1, 6, 7